Verve Therapeutics, a Cambridge, Mass.-based next-generation cardiovascular company, has launched with $58.5m in Series A funding.
The round was led by GV (formerly Google Ventures), with participation from ARCH Venture Partners, F-Prime Capital, and Biomatics Capital.
The company intends to use the funds to advance the pre-clinical programs through proof-of-concept studies.
Founded by a team of world-renowned researchers in cardiovascular genetics and pioneers of gene editing, including Sekar Kathiresan, M.D. (incoming CEO), Kiran Musunuru, M.D., Ph.D. (chief scientific advisor), MPH, and J. Keith Joung, M.D., Ph.D., Verve Therapeutics aims to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. To this end, the company has assembled a portfolio of key gene editing technologies, which includes a collaboration with Beam Therapeutics and license agreements with Harvard University and the Broad Institute of MIT and Harvard. It has also entered into a collaboration with Verily to develop and optimize nanoparticle formulations for therapeutic delivery.
Verve also has a research lab located at Pennovation Works, the University of Pennsylvania incubator space in Philadelphia.